15 Comments

CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS OF NEUTROPHIL DISORDERS

CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS OF NEUTROPHIL DISORDERS
Williams Hematology

CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS OF NEUTROPHIL DISORDERS

MARSHALL A. LICHTMAN

Classification
Clinical Manifestations

Neutropenia

Qualitative Neutrophil Abnormalities

Neutrophilia

Neutrophil-Induced Vascular or Tissue Damage
Chapter References

Neutrophil disorders can be grouped into deficiencies, or neutropenia, and excesses, or neutrophilia. The former can have the severe consequence of predisposing to infection, whereas the latter is usually a manifestation of an underlying inflammatory or neoplastic disease: the neutrophilia, per se, having no specific consequences. Neutropenia may reflect an inherited disease that is usually evident in childhood (such as congenital neutropenia), but it is more often acquired. The most common cause for neutropenia is the adverse effect of the use of a drug. Some cases of neutropenia have no evident cause. The health consequence of neutropenia is a function of the severity of the decrease in the blood neutrophil count and the abruptness and duration of the decrease. Qualitative disorders of neutrophils may lead to infection as a result of defective chemotaxis to an inflammatory site or defective microbial killing. Table 70-1 provides a comprehensive categorization of neutrophil disorders.

TABLE 70-1 CLASSIFICATION OF NEUTROPHIL DISORDERS

CLASSIFICATION
Table 70-1 lists disorders that result from a primary deficiency in neutrophil numbers or function. Neutropenia or neutrophilia may also occur as part of a disorder that affects multiple blood cell lineages, such as occurs in infiltrative diseases of the marrow or after cytotoxic drug therapy, but these are not included in this classification and are discussed in other parts of this text. In this classification, and in this section of the text, we consider diseases resulting from neutrophil deficiencies in which the neutrophil is either the only cell type affected or is the dominant cell type affected.
A pathophysiologic classification of neutrophil disorders has proved elusive. Techniques to measure mechanisms of impaired production or accelerated destruction of neutrophils are more difficult and complex than those used for red cells or platelets. The low concentration of blood neutrophils, accentuated in neutropenic states, makes radioactive labeling techniques to study the kinetics of autologous cells in neutropenic subjects technically difficult or not possible. The two compartments of neutrophils in the blood, the random disappearance of neutrophils from the circulation, the extremely short circulation time of neutrophils, the absence of techniques to measure the size of the tissue neutrophil compartment, and the disappearance of neutrophils by death or excretion from the tissue compartment also make multicompartment kinetic analysis exceedingly difficult. Also, neutropenic disorders are uncommon, and few laboratories are able, or prepared, to undertake the studies necessary to define the mechanisms of their development in sporadic cases. Therefore, efforts to understand the pathophysiology of neutropenia have had limited success. Hence, the classification of neutrophil disorders is partly pathophysiologic and partly descriptive (see Table 70-1). Although imperfect, classification does provide a language for communication and a basis for rectification as knowledge of the cause and mechanism of disease advances.
The classification is self-explanatory except in two areas. First, certain childhood syndromes have been listed under decreased neutrophilic granulopoiesis. They could have been listed under chronic hypoplastic or chronic idiopathic neutropenia; however, they seem to hold a special interest, and their pathogenesis is still disputed. Three childhood syndromes, although associated with neutropenia, are omitted because the neutropenia is part of a more global suppression of hemopoiesis: Pearson syndrome,1,2 Fanconi syndrome,3,4 and dyskeratosis congenita.5,6
A second area requiring explanation is the chronic idiopathic neutropenias. This group includes: (1) cases with normocellular marrows but an inadequate compensatory increase in granulopoiesis for the degree of neutropenia and (2) cases with hyperplastic granulopoiesis that is apparently ineffective. Unlike hypoplastic neutropenias in which the granulocyte precursors are markedly reduced or absent, precursors are present in the marrow in the idiopathic neutropenias, but the extent of effective granulopoiesis is probably low.
Qualitative disorders of neutrophils affect their ability to enter inflammatory exudates, to ingest microorganisms, or to kill ingested microorganisms (see Chap. 72).
CLINICAL MANIFESTATIONS
The clinical manifestations of decreased concentrations or abnormal function of neutrophils are principally the result of infection.
The combined deficit of neutrophils and monocytes characteristic of aplastic anemia, hairy-cell leukemia, and cytotoxic therapy leads to susceptibility to a broader spectrum of infectious agents. Increased concentrations of normal neutrophils per se have not been associated with clinical manifestations, although increased concentrations of leukemic neutrophil precursors can produce clinical manifestations of microcirculatory leukostasis (see Chap. 91).
NEUTROPENIA
The lower limit of the normal neutrophil count is about 1800/µl (1.8 × 109/liter) in subjects of European descent and 1400/µl (1.4 × 109/liter) in subjects of African descent.148,149,150,151,152,153 and 154 This finding is especially striking in Yemenite Jews, another ethnic group with very low “normal” neutrophil counts.155 A decrement in neutrophil concentration to 1000/µl (1.0 × 109/liter) usually poses little threat in the otherwise healthy individual. If the neutrophil count drops further, the risk of infection increases, and subjects chronically neutropenic as a result of a production abnormality with counts less than 500 neutrophils/µl (0.5 × 109/liter) are at risk of developing recurrent infections.156
The relationship of frequency or type of infection to neutrophil concentration is an imperfect one. The cause of the neutropenia, the coincidence of monocytopenia or lymphopenia, concurrent use of alcohol or glucocorticoids, and other factors can influence the likelihood of infection.
Infections in neutropenic subjects, not otherwise compromised, are most likely to result from gram-positive cocci and usually are superficial, involving skin, oropharynx, bronchi, anal canal, or vagina. However, any site may become infected, and gram-negative organisms, viruses, or opportunistic organisms may be involved.
A decrease in neutrophil count can occur abruptly or gradually (see Chap. 71). One type of drug-induced neutropenia is distinguished by the rapidity of onset. This abrupt-onset neutropenia is more likely to be severe and lead to symptoms. If the neutrophil count approaches zero (agranulocytosis), high fever; chills; necrotizing, painful oral ulcers (agranulocytic angina); and prostration may occur, presumably as a result of sepsis.157,158 and 159 As the disease progresses, headache, stupor, and rash may develop. In the preantibiotic era, persistent agranulocytosis had a fatality rate approaching 100 percent. Even with bactericidal, broad-spectrum antibiotics, severe, sustained neutropenia or agranulocytosis is a serious illness with a high fatality rate.
There is a decrease in the formation of pus in patients with severe neutropenia.160,161 This failure to suppurate can mislead the clinician and delay identification of the site of infection because minimal physical or radiographic findings develop. For example, lack of pneumonic consolidation is characteristic of pneumonia in granulocytopenic subjects. Exudate, swelling, heat, and regional adenopathy are much less prevalent in granulocytopenic patients. Fever is common, and local pain, tenderness, and erythema are nearly always present despite a marked reduction in neutrophils.162,163 and 164
The mechanism of neutropenia, as well as the severity of the deficiency of cells, plays a role in clinical manifestations. Chronic idiopathic (benign) neutropenia is associated with normal granulopoiesis in the marrow and is asymptomatic even when present for prolonged periods, sometimes in the face of neutrophil counts approaching zero.49 Presumably the delivery of neutrophils from marrow to tissues is sufficient to prevent infection despite the low blood pool size.50,51 Monocyte counts are normal, and this may also aid in host defenses, since these cells are effective phagocytes.
Chronic idiopathic (symptomatic) neutropenia is often associated with pyoderma and otitis media in children.55 The former is usually caused by Staphylococcus aureus, Escherichia coli, and Pseudomonas spp., and the latter is usually the result of infection by pneumococci or Pseudomonas aeruginosa. Unexplained chronic gingivitis also may be a manifestation of chronic neutropenia.165 Pneumonia, lung abscesses, stomatitis, hepatic abscesses, or infections in other sites may occur.56
Chronic cyclic neutropenia is characterized by periodic oscillations in the number of neutrophils, with the nadir occurring at about 3-week intervals.36,166 During neutropenia, patients develop malaise, fever, and buccal, labial, or lingual ulcers, and cervical adenopathy. Furuncles, carbuncles, cellulitis, infected cuts with lymphangitis, chronic gingivitis, and abscesses of the axilla or groin also may occur. Although severe infections may lead to fatality, life-threatening complications are uncommon (see Chap. 71).
Some individuals may have neutropenia because a larger proportion of their blood neutrophils is in the marginal rather than in the circulating pool. The total blood neutrophil pool is normal, and infections do not result from this atypical distribution of neutrophils.167 This type of alteration has been called pseudoneutropenia.
QUALITATIVE NEUTROPHIL ABNORMALITIES
Neutrophil function depends on the ability of neutrophils to adhere to endothelium, move, respond to chemotactic gradients, ingest microorganisms, and kill ingested pathogens. Loss of any of these functions can predispose to infection (see Chap. 72). Defects in each step of the neutrophil’s participation in the inflammatory response have been identified.168,169 Defects in cytoplasmic contractile proteins, granule synthesis or contents, or intracellular enzymes may underlie a movement, ingestion, or killing defect. These defects may be congenital or acquired. Chronic granulomatous disease102,103 and Chédiak-Higashi disease121 are two examples of the former. Among the acquired disorders are those extrinsic to the cell, such as in the movement, chemotactic, or phagocytic defects of diabetes mellitus,168,169,170 and 171 alcohol abuse,172,173 or glucocorticoid excess.174 Acquired intrinsic disorders are usually manifestations of stem cell disorders like preleukemia175 (see Chap. 91).
Severe defects in bacterial killing, such as occur in chronic granulomatous disease, result in S. aureus, Klebsiella-Aerobacter, E. coli, and other catalase-positive bacterial infections. Suppurative lymphadenitis, pneumonia, dermatitis, hepatic abscesses, osteomyelitis, and stomatitis occur, and chronic granulomatous reactions in these sites give the disease its name. Fatality rates have been high. Functional disorders may be severe, as in chronic granulomatous disease. Mild functional disorders predispose to infections that are relatively infrequent and that respond readily to antibiotics. Severe functional disorders result in suppurative lesions because neutrophil influx into inflammatory foci is not impaired, whereas agranulocytosis is associated with nonsuppurative lesions.
NEUTROPHILIA
An overabundance of neutrophils has not been shown to result in specific clinical manifestations. Neutrophils can transiently occlude capillaries, as determined by supravital microscopy, and such occlusions may reduce local blood flow transiently and contribute to the development of ischemia.124 Impairment of reperfusion of the coronary microcirculation has been thought to be dependent, in part, on neutrophil plugging of myocardial capillaries.123
NEUTROPHIL-INDUCED VASCULAR OR TISSUE DAMAGE
Neutrophil products may contribute to the pathogenesis of inflammatory skin, bowel, synovial, glomerular, and bronchial and interstitial pulmonary diseases.124,125,126,127,128,129,130,131,132,133,134,135,136,137 and 138 In addition, these products may act as mediators of tissue injury in myocardial infarction.139,140,141 and 142 Also, highly reactive oxygen products of neutrophils may be mutagens that increase the risk of neoplasia.144,145 This action may explain, for example, the development of carcinoma of the bowel in patients with chronic ulcerative colitis and the relationship between elevated leukocyte count and the occurrence of lung cancer, independent of the effect of cigarette usage.146 The oxidants, especially hypochlorous acid and chloramines, released by the neutrophil are extremely short lived and may play a role in tissue injury by inactivating several protease inhibitors in tissue fluids, permitting proteases, especially elastase, collagenase, and gelatinase, to cause tissue injury.129 Thrombogenesis has also been ascribed to leukocyte products.143
CHAPTER REFERENCES

1.
Pearson HA, Lobel JS, Kocoshis SA, et al: A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 95:976, 1979.

2.
van de Corput MP, van den Ouweland JM, Dirks RW, et al: Detection of mitochondrial DNA deletions in human skin fibroblasts of patients with Pearson’s syndrome by two-color fluorescence in situ hybridization. J Histochem Cytochem 45:55, 1997.

3.
Gordon-Smith EC, Rutherford TR: Fanconi anemia. Ballières Clin Haematol 2:139, 1989.

4.
d’Appolito M, Zelante L, Savoia A: Molecular basis of Fanconi anemia. Haematologica 83:533, 1998.

5.
Srinavin C, Trowbridge A: Dyskeratosis congenita: Clinical features and genetic aspects. J Med Genet 12:339, 1975.

6.
Dokal I: Severe aplastic anemia including Fanconi’s anemia and dyskeratosis congenita. Curr Opin Hematol 3:453, 1996.

7.
Kostmann R: Infantile genetic agranulocytosis. Acta Pediatr Scand 64:362, 1975.

8.
Tidow N, Pilz C, Teichmann B, et al: Clinical relevance of point mutations in the cytoplasmic domain of granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Blood 89:2369, 1997.

9.
Rappeport JM, Parkman R, Newburger P, et al: Correction of infantile agranulocytosis (Kostmann’s syndrome) by allogeneic transplantation. Am J Med 68:605, 1980.

10.
Kyds U, Pietsch T, Welte K: Expression of receptors for granulocyte colony-stimulating factor on neutrophils from patients with severe congenital neutropenia and cyclic neutropenia. Blood 79:1144, 1992.

11.
Bonilla MA, Gillio AP, Ruggeiro M, et al: Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 320:1574, 1989.

12.
Weston B, Todd RF III, Axtell R, et al: Severe congenital neutropenia: Clinical effects and neutrophil function during treatment with granulocyte colony-stimulating factor. J Lab Clin Med 117:282, 1991.

13.
Haas RJ, Niethammer D, Goldmann SF, et al: Congenital immunodeficiency and agranulocytosis (reticular dysgenesis) Acta Paediatr Scand 66:279, 1977.

14.
Levinsky RJ, Tiedman K: Successful bone-marrow transplantation for reticular dysgenesis. Lancet 1:671, 1983.

15.
Saunders EF, Gall G, Freedman MH: Granulopoiesis in Schwachman’s syndrome (pancreatic insufficiency and bone marrow dysfunction). Pediatrics 64:515, 1979.

16.
Woods WG, Roloff JS, Lukens JN: The occurrence of leukemia in patients with Schwachman syndrome. J Pediatr 99:425, 1981.

17.
Azzarà A, Carulli G, Ceccarelli M, et al: In vivo effectiveness of lithium on impaired neutrophil chemotaxis in Schwachman-Diamond syndrome. Acta Haematol 85:100, 1991.

18.
Lonsdale D, Doedhar SD, Mercer RD: Familial granulocytopenia associated with immunoglobulin abnormality. J Pediatr 71:760, 1967.

19.
Wetzler M, Talpaz M, Kleinerman ES, et al: A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 89:663, 1990.

20.
Kozlowski C, Evans DIK: Neutropenia associated with X-linked agammaglobulinemia. J Clin Pathol 44:388, 1991.

21.
Lux SE, Johnston RB Jr, August CS, et al: Chronic neutropenia and abnormal cellular immunity in cartilage-hair hypoplasia. N Engl J Med 282:231, 1970.

22.
Trojak JE, Polmar SH, Winkelstein JA: Immunologic studies of cartilage-hair hypoplasia in the Amish. Johns Hopkins Med J 148:157, 1981.

23.
Norio R, Raitta C, Lindahl E: Further delineation of the Cohen syndrome. Clin Genet 25:1, 1984.

24.
Warburg M, Pedersen SA, Hønlyk H: The Cohen syndrome. Ophthalmic Pediatr Genet II:7, 1990.

25.
Barth PG, Scholte HR, Berden JA, et al: An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leukocytes. J Neurol Sci 62:327, 1983.

26.
Bohurs PA, Hensels GW, Hulsebos TJM, et al: Mapping of the locus for the X-linked cardioskeletal myopathy with neutropenia and abnormal mitochondria (Barth syndrome) to Xq28. Am J Hum Genet 48:481, 1991.

27.
Bassan R, Viero P, Minetti B, et al: Myelokathexis: A rare form of chronic benign neutropenia. Br J Haematol 58:115, 1984.

28.
Wetzler M, Talpaz M, Kellagher MJ, et al: Myelokathexis. JAMA 267:2179, 1992.

29.
Lightsey AL, Parmley RT, Marsh WL, et al: Severe congenital neutropenia with unique features of dysgranulopoiesis. Am J Hematol 18:59, 1985.

30.
Koenig JM, Christensen RD: Incidence, neutrophil kinetics and natural history of neonatal neutropenia associated with maternal hypertension. N Engl J Med 321:557, 1989.

31.
Koenig JM, Christensen RD: The mechanism responsible for diminished neutrophil production in neonates delivered of women with pregnancy-induced hypertension. Am J Obstet Gynecol 165:467, 1991.

32.
Hartl PW: Drug-induced agranulocytosis, in Blood Disorders Due to Drugs and Other Agents, edited by RH Girdwood, pp 147–186. Excerpta Medica, Amsterdam, 1974.

33.
Hine LK, Gerstman BB, Wise RP, Tsang Y: Mortality resulting from blood dyscrasias in the United States, 1984. Am J Med 88:151, 1990.

34.
Pisciotta AV: Drug-induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 4:226, 1990.

35.
Julia A, Olona M, Bueno J, et al: Drug-induced agranulocytosis. Br J Haematol 79:366, 1991.

36.
Wright DG, Dale DC, Fauci AS, Wolff SM: Human cyclic neutropenia. Medicine 60:13, 1981.

37.
Tefferi A, Solberg LA, Petett RM, Willis LG: Adult-onset cyclic bicytopenia. Am J Hematol 30:181, 1989.

38.
Loughran TP Jr, Clark EA, Hammond WP: Adult-onset cyclic neutropenia is associated with increased large granular lymphocytes. Blood 68:1082, 1986.

39.
Hammond WP, Price TH, Souza LM, Dale DC: Treatment of cyclic neutropenia with granulocyte colony-stimulating factor. N Engl J Med 320:1306, 1989.

40.
Marinone G, Roncoli B, Marinone MG: Pure white cell aplasia. Semin Hematol 28:298, 1991.

41.
Morley AA, Carew JP, Baikie AG: Familial cyclic neutropenia. Br J Haematol 13:719, 1967.

42.
Hammond WP, Chatta GS, Andrews RG, Dale DC: Abnormal responsiveness of granulocyte-committed progenitor cells in cyclic neutropenia. Blood 79:2536, 1992.

43.
Dale DC, Hammond WP: Cyclic neutropenia: A clinical review. Blood Rev 2:178, 1988.

44.
Spaet TH, Dameshek W: Chronic hypoplastic neutropenia. Am J Med 13:35, 1952.

45.
Hutchinson R, Bunnell K, Thorne J: Suppression of granulopoietic progenitor cell proliferation by metabolites of the branched-chain amino acids. J Pediatr 106:62, 1985.

46.
Murdock JMC, Smith CC: Haematologic aspects of systemic disease—infection. Clin Haematol 1:619, 1972.

47.
Olson JP, Lichtman MA: Neutropenia, in Hematology for Practitioners, edited by MA Lichtman, pp 105–120. Little, Brown, Boston, 1978.

48.
Cutting HO, Lange JE: Familial-benign chronic neutropenia. Ann Intern Med 61:876, 1964.

49.
Kyle RA: Natural history of chronic idiopathic neutropenia. N Engl J Med 302:908, 1970.

50.
Wright DG, Meierovics AI, Foxley JM: Assessing the delivery of neutrophils to tissues in neutropenia. Blood 67:1023, 1986.

51.
Mant MJ, Gordon PA, Akabotu JJ: Bone marrow granulocyte reserve in chronic benign idiopathic neutropenia. Clin Lab Haematol 9:281, 1987.

52.
Logue GL, Shastri KA, Laughlin M, et al: Idiopathic neutropenia: Antineutrophil antibodies and clinical correlations. Am J Med 90:211, 1991.

53.
Jonsson OG, Buchanan GR: Chronic neutropenia during childhood. Am J Dis Child 145:232, 1991.

54.
Jakubowski AA, Souza L, Kelly F, et al: Effects of human granulocyte colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med 320:38, 1989.

55.
Pincus SH, Boxer LA, Stossel TP: Chronic neutropenia in childhood. Am J Med 61:849, 1976.

56.
Dale DC, Guerry D IV, Wewerka JR, et al: Chronic neutropenia. Medicine 58:128, 1979.

57.
Lalezari P: Alloimmune neonatal neutropenia, in Clinical Immunology and Allergy, edited by CP Engelfriet, AEG VondemBorne, p 423. Balliére Tindall, London, 1987.

58.
Fromont P, Bettaieb A, Skouri H, et al: Frequency of the polymorphonuclear neutrophil Fc receptor III deficiency in the French population and its involvement in the development of neonatal alloimmune neutropenia. Blood 79:2131, 1992.

59.
Shastri KA, Logue GL: Autoimmune neutropenia. Blood 81:1984, 1993.

60.
Bux J, Behrens G, Jaeger G, Welte K: Diagnosis and clinical course of autoimmune neutropenia in infancy: Analysis of 240 cases. Blood 91:181, 1998.

61.
Boxer LA, Greenberg MS, Boxer GJ, Stossel TP: Autoimmune neutropenia. N Engl J Med 293:748, 1975.

62.
Hadley AG, Holdurn AM, Bunch C, Chapel H: Antigranulocyte opsonic activity and autoimmune neutropenia. Br J Haematol 63:581, 1986.

63.
Hartman KR, Wright DG: Identification of autoantibodies specific for the neutrophil adhesion glycoproteins CD116/CD18 in parents with autoimmune neutropenia. Blood 78:1096, 1991.

64.
Starkebaum G, Loughran TP Jr, Gaur LK, et al: Immunogenetic similarities between patients with Felty’s syndrome and those with clonal expansion of large granular lymphocytes in rheumatoid arthritis. Arthr Rheum 40:624, 1997.

65.
Mason C, Perroux-Goummy L, Audran M: Felty’s syndrome, pseudo-Felty’s syndrome, monoclonal or polyclonal CD3 lymphocytosis of undetermined significance. Rev Rhumat 63:5, 1996.

66.
Gross WL, Schmitt WH, Csernok E: ANCA and associated diseases: immunodiagnostic and pathogenic aspects. Clin Exp Immunol 91:1, 1993.

67.
Yamato E, Fujioka Y, Masugi F, et al: Autoimmune neutropenia with anti-neutrophil autoantibody associated with Sjögren’s syndrome. Am J Med Sci 300:102, 1990.

68.
Stevens C, Peppercorn MA, Grand RJ: Crohn’s disease associated with autoimmune neutropenia. J Clin Gastroenterol 13:328, 1991.

69.
Zachee P, Daeleans R, Pollaris P, et al: Neutrophil adhesion molecules in chronic hemodialysis patients. Nephron 68:192, 1994.

70.
Knudsen F, Nielsen AH, Pedersen JO, et al: Adult respiratory distress-like syndrome during hemodialysis: relationship between activation of complement, leukopenia, and release of granulocyte elastase. Int J Artif Organs 8:187, 1985.

71.
Firkin FC, Prewett EJ, Nicholls K, Moran J: Antithymocyte globulin therapy for pure white cell aplasia. Am J Hematol 25:101, 1987.

72.
Mathieson PW, O’Neill JH, Durrant STS, et al: Antibody-mediated pure neutrophil aplasia, recurrent myasthenia gravis and previous thymoma. Q J Med 74:57, 1990.

73.
Joyce RA, Boggs DR, Hasiba U, Srodes CH: Marginal neutrophil pool size in normal subjects and neutropenic patients as measured by epinephrine infusion. J Lab Clin Med 88:614, 1976.

74.
Herring WB, Smith LG, Walker RI, Herion JC: Hereditary neutrophilia. Am J Med 56:729, 1974.

75.
Ward HN, Reinhard EH: Chronic idiopathic leukocytosis. Ann Intern Med 75:193, 1971.

76.
Joyce RA, O’Donnell J, Sanghvi J, Westerman MP: Asplenia and abnormal neutrophil kinetics in chronic idiopathic neutrophilia. Am J Med 69:633, 1980.

77.
Hilts SV, Shaw CC: Leukemoid blood reactions. N Engl J Med 149:343, 1953.

78.
Marsh JC, Boggs DR, Cartwright GE, Wintrobe MM: Neutrophil kinetics in acute infection. J Clin Invest 46:1943, 1967.

79.
McKee LC: Excess leukocytosis (leukemoid reactions) associated with malignant diseases. South Med J 78:1475, 1985.

80.
Bishop CR: Leukokinetic studies: XIII. A non-steady state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J Clin Invest 47:249, 1968.

81.
Murphy DL, Goodwin FK, Bunney WE: Leukocytosis during lithium treatment. Am J Psychiatry 127:135, 1971.

82.
Huang W, McNeely MC: Neutrophilic tissue reactions. Adv Dermatol 13:33, 1998.

83.
Petitti DB, Kipp H: The leukocyte count: association with intensity of smoking and persistence of effect after quitting. Am J Epidemiol 123:89, 1986.

84.
Athens JW, Haab OP, Raab SO, et al: Leukokinetic studies: IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest 40:989, 1961.

85.
Arnaout MA, Pitt J, Cohen HJ, et al: Deficiency of membrane glycoprotein (gp 150) in a boy with recurrent bacterial infections. N Engl J Med 306:693, 1982.

86.
Rotrosen D, Gallin JI: Disorders of phagocyte function. Annu Rev Immunol 5:127, 1987.

87.
Klebanoff SJ, Clark RA: The Neutrophil: Function and Clinical Disorders. North-Holland, Amsterdam, 1978.

88.
Yang KD, Hill HR: Neutrophil function disorders: Pathophysiology, prevention and therapy. J Pediatr 119:343, 1991.

89.
Gallin J: Leukocyte adherence-related glycoproteins LFA-1, Mo-1, and p 150,95: A new group of monoclonal antibodies, a new disease and a possible opportunity to understand the molecular basis of leukocyte adherence. J Infect Dis 152:661, 1985.

90.
Anderson DC, Springer TA: Leukocyte adhesion deficiency: An inherited defect in Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med 38:175, 1987.

91.
Etzioni A, Frydman M, Pollock S, et al: Recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 327:1789, 1992.

92.
Davies KA, Toothill VJ, Savill J, et al: A 19-year-old man with leukocyte adhesion deficiency. Clin Exp Immunol 84:223, 1991.

93.
MacGregor RR, Spagnulo PJ, Lentnek AL: Inhibition of granulocyte adherence by ethanol, prednisone, and aspirin, measured with an assay system. N Engl J Med 291:642, 1974.

94.
Clark RA: Disorders of granulocyte chemotaxis: An analytical review. Clin Immunol Immunopathol 15:52, 1980.

95.
Rotrosen D, Gallen JI: Disorders of phagocyte function. Annu Rev Immunol 5:127, 1987.

96.
Miller ME, Oski FA, Harris MB: Lazy-leucocyte syndrome. A new disorder of neutrophil function. Lancet 1:665, 1971.

97.
Boxer LA, Hedley-White ET, Stossel TP: Neutrophil actin dysfunction and abnormal neutrophil behavior. N Engl J Med 291:1043, 1974.

98.
Coates TD, Torkildson JC, Torres M, et al: An inherited defect of neutrophil motility and microfilamentous cytoskeleton associated with abnormalities in 47-Kd and 89-Kd proteins. Blood 78:1338, 1991.

99.
Meyle J: Leukocyte adhesion deficiency and prepubertal periodontitis. Periodontology 2000:6,1994.

100.
Hill HR, Augustine NH, Jaffe HS: Human recombinant interferon gamma enhances neonatal PMN activation and movement increases free intracellular calcium. J Exp Med 173:767, 1991.

101.
Klempner MS, Noring R, Meir JW, Atkins MB: An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322:959, 1990.

102.
Meischi C, Roos D: The molecular basis of chronic granulomatous disease. Springer Sem Immunopathol 19:417, 1998.

103.
Segal AW: Biochemistry and molecular biology of chronic granulomatous disease. J Inherited Metab Dis 15:683, 1992.

104.
Bogomolski-Yahalom V, Matzner Y: Disorders of neutrophil function. Blood Reviews 9:183, 1995.

105.
Lehrer RI, Cline MJ: Leukocyte myeloperoxidase deficiency and disseminated candidiasis: The role of myeloperoxidase in resistance to Candida infection. J Clin Invest 48:1478, 1989.

106.
Gerber CE, Kuci S, Zipfel M, et al: Phagocytic activity and oxidative burst of granulocytes in persons with myeloperoxidase deficiency. Eur J Clin Chem Clin Biochem 34:901, 1996.

107.
Jeppson JD, Jaffe HW, Hill HR: Use of recombinant human interferon gamma enhances neutrophil chemotactic responses in Job syndrome of hypergammaglobulin E and recurrent infections. J Pediatr 118:383, 1991.

108.
Cooper MR, DeChatelet LR, McCall CE, et al: Complete deficiency of leukocyte glucose-6-phosphate dehydrogenase with defective bactericidal activity. J Clin Invest 51:769, 1972.

109.
Bjerknes R, Vindenes H, Pitkänen J, et al: Altered polymorphonuclear neutrophilic granulocyte functions in patients with large burns. J Trauma 29:847, 1989.

110.
Couper R, Kapellushnik J, Griffiths AM: Neutrophil dysfunction in glycogen storage disease Ib: Association with Crohn’s-like colitis. Gastroenterology 100:549, 1991.

111.
Schroten H, Wendel U, Burdach S, et al: Colony-stimulating factors for neutropenia in glycogen storage disease Ib. Lancet 337:736, 1991.

112.
Tamura DY, Moore EE, Patrick DA, et al: Clinically relevant concentrations of ethanol attenuate primed neutrophil bacteriocidal activity. J Trauma 44:320, 1998.

113.
Porter CJ, Burden RP, Morgan AG, et al: Impaired bacterial killing and hydrogen peroxide production by polymorphonuclear neutrophils in end-stage renal failure. Nephron 77:479, 1997.

114.
Davidson WM, Milner RDG, Lawlor SD: Giant neutrophil leukocytes: An inherited anomaly. Br J Haematol 6:339, 1960.

115.
Undritz VE: Eine neue Sippe mit Erblich—Konstitutioneller Hochsegmentierung der Neutrophilenkerne. Schweiz Med Wochenschr 94:1365, 1964.

116.
Falloon J, Gallin JI: Neutrophil granules in health and disease. J Allergy Clin Immunol 77:653, 1986.

117.
Lomax KJ, Gallin JI, Benz EJ Jr, et al: Neutrophil specific granule deficiency likely results from an abnormality of expression of a subset of secretory protein genes. Blood 70(suppl 1):93a, 1988.

118.
Rebuck JW, Barth CL, Petz AJ: New leucocytic dysfunction at the inflammatory sites in Hegglines, Hurler’s and Pelger-Huët anomalous states. Fed Proc 22:427, 1963.

119.
Reilly WA, Lindsay S: Gargoylism (lipochondrodystrophy): A review of clinical observations in eighteen cases. Am J Dis Child 75:595, 1948.

120.
Oski FA, Naiman JL, Allen DM, Diamond LK: Leukocytic inclusions—Döhle bodies-associated with platelet abnormality (the May-Hegglin anomaly): Report of a family and review of the literature. Blood 20:657, 1962.

121.
Bara KY: Chédiak-Higashi syndrome. Scand J Haematol 37:1627, 1987.

122.
Ganz T, Metcalf JA, Gallin JI, et al: Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chédiak-Higashi syndrome and specific granule deficiency. J Clin Invest 82:552, 1988.

123.
Dahlgren MD, Petersen MA, Engler RL, Schmid-Schönbein GW: Leukocyte rheology in cardiac ischemia, in White Cell Mechanics: Basic Science and Clinical Aspects, edited by H Meiselman, MA Lichtman, PL La Celle, pp 271–283. Liss, New York, 1984.

124.
Schmid-Schönbein GN: Leukocyte kinetics in the microcirculation. Biorheology 24:139, 1987.

125.
Gallin JI: Neutrophil specific granules: A fuse that ignites the inflammatory response. Clin Res 32:320, 1984.

126.
Janoff A: Elastase in tissue injury. Annu Rev Med 36:207, 1985.

127.
Smedly LA, Tonnesen MG, Sandhaus RA, et al: Neutrophil-mediated injury to endothelial cells: Enhancement by endotoxin and essential role of neutrophil elastase. J Clin Invest 77:1233, 1986.

128.
Malech HL, Gallin JI: Neutrophils in human diseases. N Engl J Med 317:687, 1987.

129.
Weiss SJ: Tissue destruction by neutrophils. N Engl J Med 320:365, 1989.

130.
Meiselman H, Lichtman MA, La Celle PL (eds): White Cell Mechanics: Basic Science and Clinical Aspects. Liss, New York, 1984.

131.
Swank DW, Moore SB: Roles of the neutrophil and other mediators in adult respiratory distress syndrome. Mayo Clin Proc 64:1118, 1989.

132.
MacNee W, Wiggs B, Balzberg AS, Hogg JC: The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med 321:924, 1989.

133.
Parker CW: Neutrophil mechanisms. Am Rev Resp Dis 143:559, 1991.

134.
Martin TR, Pistorese BP, Hudson LD, Maunder RJ: The function of lung and blood neutrophils in patients with the adult respiratory distress syndrome. Implication for the pathogenesis of lung infections. Am Rev Resp Dis 144:254, 1991.

135.
Godek JE: Adverse effects of neutrophils on the lung. Am J Med 92(suppl 6A):27S, 1992.

136.
Palmgren MS, deShazo RO, Cater RM, et al: Mechanisms of neutrophil damage to human alveolar extracellular matrix: The role of serine and metalloproteases. J Allergy Clin Immunol 89:905, 1992.

137.
Boventre JV, Colvin RB: Adhesion molecules in renal disease. Curr Opin Nephrol Hypertension 5:254,1996.

138.
Weiss ST, Segal MR, Sparrow D, Wager C: Relation of FEV1 and peripheral blood leukocyte count to total mortality. Am J Epidemiol 142:493, 1995.

139.
Bednar M, Smith B, Pinto A, Mullane KM: Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function. Circ Res 57:131, 1985.

140.
Allan G, Bhattacherjee P, Brook CD, et al: Myeloperoxidase activity as a quantitative marker of polymorphonuclear leukocyte accumulation into an experimental myocardial infarct—the effect of ibuprofen on infarct size and polymorphonuclear leukocyte accumulation. J Cardiovasc Pharmacol 7:1154, 1985.

141.
Ranjadayalan K, Umachandran V, Daviews SW, et al: Thrombolytic treatment in acute myocardial infarction: Neutrophil activation, peripheral leucocyte responses, and myocardial injury. Br Heart J 66:10, 1991.

142.
Welbourn CRB, Goldman G, Paterson IS, et al: Pathophysiology of ischaemia reperfusion injury: Central role of the neutrophil. Br J Surg 78:651, 1991.

143.
Schaub RG, Yamashita A, Simmons CA, et al: Leukocyte-mediated large vein injury and thrombosis: Pharmacologic intervention with lipoxygenase inhibitors, in Leukocyte Emigration and Its Sequelae, edited by HZ Morat, pp 62–68. Karger, Basel, 1987.

144.
Weitzman SA, Weitburg AB, Clark EP, Stossel TP: Phagocytes as carcinogens: Malignant transformation produced by human neutrophil. Science 227:1231, 1985.

145.
Trush MA, Seed JL, Kensler TW: Oxidant-dependent metabolic activation of polycyclic aromatic hydrocarbons by phorbol ester–stimulated human polymorphonuclear leukocytes: Possible link between inflammation and cancer. Proc Natl Acad Sci USA 82:5194, 1985.

146.
Phillips AN, Neaton JD, Cook DG, et al: The leukocyte count and risk of lung cancer. Cancer 69:680, 1992.

147.
Fadlon E, Vordermeier S, Pearson TC, et al: Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show adhesion to vascular endothelium and increased expression of CD64. Blood 91:266, 1998.

148.
Orfanakis NG, Ostlund RE, Bishop CR, Athens JW: Normal blood leukocyte concentration values. Am J Clin Pathol 53:649, 1970.

149.
Rumke CL, Brezemer PD, Kuik DJ: Normal values and least significant differences for differential leukocyte counts. J Chronic Dis 28:661, 1975.

150.
England JM, Bain BJ: Total and differential leukocyte count. Br J Haematol 33:1, 1976.

151.
Broun GO, Herbeg FK, Hamilton JR: Leukopenia in Negroes. N Engl J Med 275:1410, 1966.

152.
Rippey JJ: Leukopenia in West Indians and Africans. Lancet 2:44, 1967.

153.
Karakyalcin G, Rosner F, Saurtsky A: Pseudoneutropenia in Negroes. NY State J Med 72:1815, 1972.

154.
Reed WW, Diehl LF: Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 151:501, 1991.

155.
Shoenfeld Y, Weinberger A, Avishar R, et al: Familial leukopenia among Yemenite Jews. Isr J Med Sci 14:1271, 1978.

156.
Bodey GP, Buckley M, Sathe YS: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328, 1966.

157.
Kracke RR: Recurrent agranulocytosis. Am J Clin Pathol 1:385, 1931.

158.
Gorlin RJ, Chaudhry AP: The oral manifestations of cyclic (periodic) neutropenia. Arch Dermatol 82:344, 1960.

159.
Levine S: Neutropenia with marked periodontal lesions. Oral Surg 12:310, 1959.

160.
Boggs DR: The cellular composition of inflammatory exudates in human leukemia. Blood 15:466, 1960.

161.
Dale DC, Wolff SM: Skin window studies of the acute inflammatory responses of neutropenic patients. Blood 38:138, 1971.

162.
Sickles EA, Green WH, Wiernick PH: Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 135:715, 1975.

163.
Russin SJ, Fillipo BH, Adler AG: Neutropenia in adults. Postgrad Med 88:209, 1990.

164.
Welte K, Boxer LA: Severe chronic neutropenia; pathophysiology and therapy. Sem Hematol 34:267, 1997.

165.
Kyle RA, Linman JW: Gingivitis and chronic idiopathic neutropenia. Mayo Clin Proc 45:494, 1970.

166.
Wright DG, Dale DC, Fauci AS, Wolff SM: Human cyclic neutropenia: Clinical review and long-term follow-up of patients. Medicine 60:1, 1981.

167.
Joyce RA, Boggs DR, Hasiba U, Srodes CH: Marginal neutrophil pool size in normal subjects and neutropenic patients as measured by epinephrine infusion. J Lab Clin Med 88:614, 1976.

168.
Baehner RL: Neutrophil dysfunction associated with states of chronic and recurrent infection. Pediatr Clin North Am 27:377, 1980.

169.
Gallin JI, Wright DG, Malech HL, et al: Disorders of phagocyte chemotaxis. Ann Intern Med 92:520, 1980.

170.
Mowat AG, Baum J: Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284:621, 1971.

171.
Tan JS, Anderson JL, Watanakunakorn C, et al: Neutrophil dysfunction in diabetes mellitus. J Lab Clin Med 85:26, 1975.

172.
Brayton RG, Stokes PE, Schwartz MS, Louria DB: Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis, and intracellular killing. N Engl J Med 282:123, 1970.

173.
Liu YK: The effect of alcohol on granulocytes and lymphocytes. Semin Hematol 17:130, 1980.

174.
Dale DC, Fauci AS, Dupont G IV, Wolff SM: Comparison of agents producing a neutrophilic leukocytosis in man: Hydrocortisone, prednisone, endotoxin and etiocholanoline. J Clin Invest 56:808, 1975.

175.
Breton-Gorius J: Abnormalities of granulocytes and megakaryocytes in preleukemic syndromes, in Preleukemia, edited by F Schmalzl, K-P Helbriegel, p 24. Springer-Verlag, Berlin, 1979.

176.
Reding MT, Hibbs JR, Morrison VA, et al: Diagnosis and outcome of 100 consecutive patients with extreme granulocytic leukocytosis. Amer J Med 104:12, 1998.

177.
Watanabe M, Ono K, Ozeki Y, et al: Production of granulocyte-macrophage colony-stimulating factor in a patient with metastatic chest wall large cell carcinoma. Jap J Clin Oncol 28:559, 1998.

178.
Salloum E, Stoessel KM, Cooper DL: Hyperleukocytosis and retinal hemorrhages after chemotherapy and filgrastim administration for peripheral blood progenitor cell mobilization. Bone Marrow Transpl 21:835, 1998.

179.
Crockard AD, Boylan MT, Droogan AG, et al: Methylprednisolone-induced neutrophil leukocytosis-down-modulation of neutrophil L-selectin and Mac-1 expression and induction of colony-stimulating factor. Inter J Clin Lab Invest 28:110, 1998.

180.
Ceddia MA, Price EA, Kohlmeier CK, et al: Differential leukocytosis and lymphocyte mitogenic response to acute maximal exercise in the young and old. Med Sci Sport Exer 31:829, 1999.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

Advertisements

15 comments on “CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS OF NEUTROPHIL DISORDERS

  1. Thanks for that cool health tip. I will definitely use it for my son next time 🙂

  2. […] CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS … […]

  3. … [Trackback]…

    […] Read More here: medtextfree.wordpress.com/2012/01/03/chapter-70-classification-and-clinical-manifestations-of-neutrophil-disorders/ […]…

  4. […] CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS … January 14th, 2012 | […]

  5. […] #split {}#single {}#splitalign {margin-left: auto; margin-right: auto;}#singlealign {margin-left: auto; margin-right: auto;}#splittitlebox {text-align: center;}#singletitlebox {text-align: center;}.linkboxtext {line-height: 1.4em;}.linkboxcontainer {padding: 7px 7px 7px 7px;background-color:#eeeeee;border-color:#000000;border-width:0px; border-style:solid;}.linkboxdisplay {padding: 7px 7px 7px 7px;}.linkboxdisplay td {text-align: center;}.linkboxdisplay a:link {text-decoration: none;}.linkboxdisplay a:hover {text-decoration: underline;} function opensingledropdown() { document.getElementById('singletablelinks').style.display = ''; document.getElementById('singlemouse').style.display = 'none'; } function closesingledropdown() { document.getElementById('singletablelinks').style.display = 'none'; document.getElementById('singlemouse').style.display = ''; } Lithium – The Misunderstood Mineral Part 1Medical Journal of Australia editor responds to homebirth study concernsMood Stabilizers for Bipolar Disorder and Bipolar DatingRisks and Side Effects of Lithium for Treating Bipolar DisorderHow I Fight Manic DepressionWhat is the most effective form of treatment for depression and anxiety?CHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS OF NEUTROPHIL DISORDERS […]

  6. […] #split {}#single {}#splitalign {margin-left: auto; margin-right: auto;}#singlealign {margin-left: auto; margin-right: auto;}#splittitlebox {text-align: center;}#singletitlebox {text-align: center;}.linkboxtext {line-height: 1.4em;}.linkboxcontainer {padding: 7px 7px 7px 7px;background-color:#eeeeee;border-color:#000000;border-width:0px; border-style:solid;}.linkboxdisplay {padding: 7px 7px 7px 7px;}.linkboxdisplay td {text-align: center;}.linkboxdisplay a:link {text-decoration: none;}.linkboxdisplay a:hover {text-decoration: underline;} function opensingledropdown() { document.getElementById('singletablelinks').style.display = ''; document.getElementById('singlemouse').style.display = 'none'; } function closesingledropdown() { document.getElementById('singletablelinks').style.display = 'none'; document.getElementById('singlemouse').style.display = ''; } How Much Should I Cut Off of a Cuban Cigar Using a Cigar Cutter? : Travel and LeisureECIG: The brand new Era of Cigarette smokingThe Surprising Popularity of Cigar SmokingWhat’s New With Blu CigsGamespy Arcade AccountCHAPTER 70 CLASSIFICATION AND CLINICAL MANIFESTATIONS OF NEUTROPHIL DISORDERS […]

  7. you definitely love chanel bags prices for gift fxwinter20off

  8. Functionality of your fashionable substitute without removing of an infection would have lead to terrible results.

  9. Howdy are using WordPress for your blog platform? I’m new to the blog world but I’m trying to get started and set up my own. Do you need any html coding knowledge to make your own blog? Any help would be really appreciated!

  10. Its wonderful as your other content : D, thankyou for posting . “Even Albert Einstein reportedly needed help on his 1040 form.” by Ronald Reagan.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: